You are here: Home > Prescription(RX) Drugs > D > Diazepam (Barr Laboratories Inc.)

Name:Diazepam
Manufacturer:Barr Laboratories Inc.
Category:Prescription Marketed Drugs


DIAZEPAM TABLETS USP

DIAZEPAM - diazepam tablet 
Barr Laboratories Inc.

----------

DIAZEPAM TABLETS USP

Rx only

Revised JANUARY 2008
11001307

BARR LABORATORIES, INC.

DESCRIPTION

Diazepam is a benzodiazepine derivative. Chemically, diazepam is 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one. It is a colorless crystalline compound, insoluble in water. Its structural formula is as follows:

Diazepam Structural Formula

Diazepam is available in 2 mg, 5 mg and 10 mg tablets for oral administration.

Inactive Ingredients

Croscarmellose cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose. 

Colors

 FD&C blue #1 (10 mg only), D&C yellow #10 (5 mg only).

PHARMACOLOGY

In animals, diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Diazepam, unlike chlorpromazine and reserpine, has no demonstrable peripheral autonomic blocking action, nor does it produce extrapyramidal side effects; however, animals treated with diazepam do have a transient ataxia at higher doses. Diazepam was found to have transient cardiovascular depressor effects in dogs. Long-term experiments in rats revealed no disturbances of endocrine function.

Oral LD50 of diazepam is 720 mg/kg in mice and 1240 mg/kg in rats.

Intraperitoneal administration of 400 mg/kg to a monkey resulted in death on the sixth day.

Reproduction Studies

A series of rat reproduction studies was performed with diazepam in oral doses of 1, 10, 80 and 100 mg/kg. At 100 mg/kg there was a decrease in the number of pregnancies and surviving offspring in these rats. Neonatal survival of rats at doses lower than 100 mg/kg was within normal limits. Several neonates in these rat reproduction studies showed skeletal or other defects. Further studies in rats at doses up to and including 80 mg/kg/day did not reveal teratological effects on the offspring.

In humans, measurable blood levels of diazepam were obtained in maternal and cord blood, indicating placental transfer of the drug.

INDICATIONS

Diazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.

In acute alcohol withdrawal, diazepam tablets may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.

Diazepam tablets are a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome.

Oral diazepam tablets may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.

The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.

CONTRAINDICATIONS

Diazepam tablets are contraindicated in patients with a known hypersensitivity to this drug and, because of lack of sufficient clinical experience, in pediatric patients under 6 months of age. It may be used in patients with open angle glaucoma who are receiving appropriate therapy, but is contraindicated in acute narrow angle glaucoma.

WARNINGS

Diazepam tablets are not of value in the treatment of psychotic patients and should not be employed in lieu of appropriate treatment. As is true of most preparations containing CNS-acting drugs, patients receiving diazepam should be cautioned against engaging in hazardous occupations requiring complete mental alertness such as operating machinery or driving a motor vehicle.

As with other agents which have anticonvulsant activity, when diazepam is used as an adjunct in treating convulsive disorders, the possibility of an increase in the frequency and/or severity of grand mal seizures may require an increase in the dosage of standard anticonvulsant medication. Abrupt withdrawal of diazepam in such cases may also be associated with temporary increase in the frequency and/or severity of seizures.

Since diazepam has a central nervous system depressant effect, patients should be advised against the simultaneous ingestion of alcohol and other CNS-depressant drugs during diazepam therapy.

Usage in Pregnancy: An increased risk of congenital malformations associated with the use of minor tranquilizers (diazepam, meprobamate and chlordiazepoxide) during the first trimester of pregnancy has been suggested in several studies. Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physicians about the desirability of discontinuing the drug.

Management of Overdosage

Manifestations of diazepam tablet overdosage include somnolence, confusion, coma and diminished reflexes. Respiration, pulse and blood pressure should be monitored, as in all cases of drug overdosage, although, in general, these effects have been minimal following overdosage. General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. As with the management of intentional overdosage with any drug, it should be borne in mind that multiple agents may have been ingested.

Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation, and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose. Patients treated with flumazenil should be monitored for resedation, respiratory depression, and other residual benzodiazepine effects for an appropriate period after treatment. The prescriber should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose. The complete flumazenil package insert including CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS should be consulted prior to use.

Withdrawal symptoms of the barbiturate type have occurred after discontinuation of benzodiazepines (see DRUG ABUSE AND DEPENDENCE section).

PRECAUTIONS

If diazepam tablets are to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed—particularly with known compounds which may potentiate the action of diazepam, such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants. The usual precautions are indicated for severely depressed patients or those in whom there is any evidence of latent depression; particularly the recognition that suicidal tendencies may be present and protective measures may be necessary. The usual precautions in treating patients with impaired renal or hepatic function should be observed.

In elderly and debilitated patients, it is recommended that the dosage be limited to the smallest effective amount to preclude the development of ataxia or oversedation (2 mg to 2½ mg once or twice daily, initially, to be increased gradually as needed and tolerated).

The clearance of diazepam and certain other benzodiazepines can be delayed in association with Tagamet (cimetidine) administration. The clinical significance of this is unclear.

Information for Patients

To assure the safe and effective use of benzodiazepines, patients should be informed that, since benzodiazepines may produce psychological and physical dependence, it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 6 months have not been established.

ADVERSE REACTIONS

Side effects most commonly reported were drowsiness, fatigue and ataxia. Infrequently encountered were confusion, constipation, depression, diplopia, dysarthria, headache, hypotension, incontinence, jaundice, changes in libido, nausea, changes in salivation, skin rash, slurred speech, tremor, urinary retention, vertigo and blurred vision. Paradoxical reactions such as acute hyperexcited states, anxiety, hallucinations, increased muscle spasticity, insomnia, rage, sleep disturbances and stimulation have been reported; should these occur, use of this drug should be discontinued.

Because of isolated reports of neutropenia and jaundice, periodic blood counts and liver function tests are advisable during long-term therapy. Minor changes in EEG patterns, usually low-voltage fast activity, have been observed in patients during and after diazepam therapy and are of no known significance.

DRUG ABUSE AND DEPENDENCE

Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (e.g., convulsions, tremor, abdominal and muscle cramps, vomiting, and sweating), have occurred following abrupt discontinuance of diazepam. The more severe withdrawal symptoms have usually been limited to those patients who received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuation of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving diazepam or other psychotropic agents because of the predisposition of such patients to habituation and dependence.

DOSAGE AND ADMINISTRATION

Dosage should be individualized for maximum beneficial effect. While the usual daily dosages given below will meet the needs of most patients, there will be some who may require higher doses. In such cases dosage should be increased cautiously to avoid adverse effects.

ADULTS: USUAL DAILY DOSAGE:

Management of Anxiety Disorders and Relief of Symptoms of Anxiety

Depending upon severity of symptoms –2 mg to 10 mg, 2 to 4 times daily

Symptomatic Relief in Acute Alcohol Withdrawal

10 mg, 3 or 4 times during the first 24 hours, reducing to 5 mg, 3 or 4 times daily as needed

Adjunctively for Relief of Skeletal Muscle Spasm

2 mg to 10 mg, 3 or 4 times daily

Adjunctively in Convulsive Disorders

2 mg to 10 mg, 2 to 4 times daily

Geriatric Patients, or in the presence of debilitating disease

2 mg to 2½ mg, 1 or 2 times daily initially; increase gradually as needed and tolerated

PEDIATRIC PATIENTS:

Because of varied responses to CNS-acting drugs, initiate therapy with lowest dose and increase as required. Not for use in pediatric patients under 6 months.

1 mg to 2½ mg, 3 or 4 times daily initially; increase gradually as needed and tolerated

HOW SUPPLIED

Diazepam Tablets, USP are available as:

2 mg: White, round, flat-faced, beveled-edge, bisected tablet. Debossed with stylized barr on one side and 555/163 on the other side. Available in bottles of:
100 Tablets NDC 0555-0163-02
500 Tablets NDC 0555-0163-04
1000 Tablets NDC 0555-0163-05
5000 Tablets NDC 0555-0163-06
5 mg: Yellow, round, flat-faced, beveled-edge, bisected tablet. Debossed with stylized barr on one side and 555/363 on the other side. Available in bottles of:
100 Tablets NDC 0555-0363-02
500 Tablets NDC 0555-0363-04
1000 Tablets NDC 0555-0363-05
5000 Tablets NDC 0555-0363-06
10 mg: Blue, round, flat-faced, beveled-edge, bisected tablet. Debossed with stylized barr on one side and 555/164 on the other side. Available in bottles of:
100 Tablets NDC 0555-0164-02
500 Tablets NDC 0555-0164-04
1000 Tablets NDC 0555-0164-05
5000 Tablets NDC 0555-0164-06

Dispense with child-resistant closure in a tight, light-resistant container.

Store at 20˚ to 25˚C (68˚ to 77˚F) [See USP Controlled Room Temperature].

BARR LABORATORIES, INC.
POMONA, NY 10970
Revised JANUARY 2008
BR-0163, 0164, 0363

PRINCIPAL DISPLAY PANEL

Diazepam Tablets, USP 2 mg 100s Label

Diazepam Tablets 2 mg 100 Tablets Label Text

NDC 0555-0163-02

BARR LABORATORIES, INC.

CIV

Diazepam

Tablets, USP

2 mg

Rx only

100 Tablets

PRINCIPAL DISPLAY PANEL

Diazepam Tablets, USP 5 mg 100s Label

5 mg 100 Tablets Label Text

NDC 0555-0363-02

BARR LABORATORIES, INC.

CIV

Diazepam

Tablets, USP

5 mg

Rx only

100 Tablets

PRINCIPAL DISPLAY PANEL

Diazepam Tablets, USP 10 mg 100s Label

Diazepam Tablets 10 mg 100 Tablets Label Text

NDC 0555-0164-02

BARR LABORATORIES, INC.

CIV

Diazepam

Tablets, USP

10 mg

Rx only

100 Tablets


DIAZEPAM 
diazepam tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0555-0163
Route of Administration ORAL DEA Schedule CIV    
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
DIAZEPAM (DIAZEPAM) DIAZEPAM 2 mg
Inactive Ingredients
Ingredient Name Strength
CROSCARMELLOSE SODIUM  
LACTOSE MONOHYDRATE  
MAGNESIUM STEARATE  
CELLULOSE, MICROCRYSTALLINE  
Product Characteristics
Color WHITE Score 2 pieces
Shape ROUND Size 8mm
Flavor Imprint Code barr;555;163
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0555-0163-02 100 TABLET ( TABLET) in 1 BOTTLE None
2 NDC:0555-0163-04 500 TABLET ( TABLET) in 1 BOTTLE None
3 NDC:0555-0163-05 1000 TABLET ( TABLET) in 1 BOTTLE None
4 NDC:0555-0163-06 5000 TABLET ( TABLET) in 1 BOTTLE None

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA070152 01/19/2011

DIAZEPAM 
diazepam tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0555-0363
Route of Administration ORAL DEA Schedule CIV    
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
DIAZEPAM (DIAZEPAM) DIAZEPAM 5 mg
Inactive Ingredients
Ingredient Name Strength
CROSCARMELLOSE SODIUM  
LACTOSE MONOHYDRATE  
MAGNESIUM STEARATE  
CELLULOSE, MICROCRYSTALLINE  
D&C YELLOW NO. 10  
Product Characteristics
Color YELLOW Score 2 pieces
Shape ROUND Size 8mm
Flavor Imprint Code barr;555;363
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0555-0363-02 100 TABLET ( TABLET) in 1 BOTTLE None
2 NDC:0555-0363-04 500 TABLET ( TABLET) in 1 BOTTLE None
3 NDC:0555-0363-05 1000 TABLET ( TABLET) in 1 BOTTLE None
4 NDC:0555-0363-06 5000 TABLET ( TABLET) in 1 BOTTLE None

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA070153 01/19/2011

DIAZEPAM 
diazepam tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0555-0164
Route of Administration ORAL DEA Schedule CIV    
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
DIAZEPAM (DIAZEPAM) DIAZEPAM 10 mg
Inactive Ingredients
Ingredient Name Strength
CROSCARMELLOSE SODIUM  
LACTOSE MONOHYDRATE  
MAGNESIUM STEARATE  
CELLULOSE, MICROCRYSTALLINE  
FD&C BLUE NO. 1  
Product Characteristics
Color BLUE Score 2 pieces
Shape ROUND Size 8mm
Flavor Imprint Code barr;555;164
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0555-0164-02 100 TABLET ( TABLET) in 1 BOTTLE None
2 NDC:0555-0164-04 500 TABLET ( TABLET) in 1 BOTTLE None
3 NDC:0555-0164-05 1000 TABLET ( TABLET) in 1 BOTTLE None
4 NDC:0555-0164-06 5000 TABLET ( TABLET) in 1 BOTTLE None

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA070154 01/19/2011

Labeler - Barr Laboratories Inc. (802716563)

Revised: 01/2011 Barr Laboratories Inc.



Source: http://dailymed.nlm.nih.gov
Reproduced with permission of U.S. National Library of Medicine


Copyright © 2017 Drugsdb.eu by Dionisios Fentas || Terms of Use

Loading

Prescription Marketed Drugs Alphabetically
A| B| C| D| E| F| G| H| I| J| K| L| M| N| O| P| Q| R| S| T| U| V| W| X| Y| Z| 0-9

Categories:
Prescription(RX) Drugs
Over-the-counter (OTC) Drugs
Homeopathic Drugs
Animal Drugs
Feedback